COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
24 hedge funds and large institutions have $7.48M invested in COSCIENS Biopharma Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
8,900% more call options, than puts
Call options by funds: $90K | Put options by funds: $1K
541% more capital invested
Capital invested by funds: $1.17M → $7.48M (+$6.32M)
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
41% more funds holding
Funds holding: 17 → 24 (+7)
0.11% more ownership
Funds ownership: 0.04% → 0.15% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$2.38M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$803K |
| 3 |
Morgan Stanley
New York
|
+$791K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$265K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$44K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$30.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$29K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$19K |
| 5 |
BA
Ballew Advisors
Jackson,
Mississippi
|
-$4K |
CSCI Hedge Fund Activity: Q4 2018 in Review
24 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2018, worth a combined $7.48M — up 541% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CSCI positions and 5 closed out — a net gain of 8 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $2.38M. The largest seller was Virtu Financial, exiting entirely with an estimated $44K sold.
- 24 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2018, up from 17 in Q3 2018.
- Funds reported $7.48M of COSCIENS Biopharma Inc. Common Stock stock for Q4 2018, up 541% quarter-over-quarter.
- 13 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2018 and 5 closed out, a net change of +8 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2018 was J. Goldman & Co, an estimated $2.38M added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2018 was Virtu Financial, an estimated $44K sold.
Based on aggregated 13F filings for Q4 2018.